METHODS:
The Hb A 1c in the 12 months immediately before the unit change (October 2010 to September 2011) was compared with the 12 months after (October 2011 to September 2012). Also, the subsequent change in Hb A 1c in patients who had poor glycemic control [Hb A 1c Ͼ8% (64 mmol/mol)], either before or after the unit change, was compared.
RESULTS:
Over the 2 years, 44 721 Hb A 1c measurements were requested on 13 197 (7247 male, 5950 female) known diabetes patients. The population Hb A 1c was no different between years, with a median [interquartile range (IQR)] value of 7.5% (6.6%-8.7%) after the change and 7.5% (6.5-8.7) before (P ϭ 0.34). The subsequent change in Hb A 1c following a raised (Ͼ8%) result was the same regardless of whether the initial value reported was in DCCT or SI units [median (IQR) change in Hb A 1c Ϫ0.2% (Ϫ0.9% to 0.3%), n ϭ 4316, following a DCCT result, vs Ϫ0.2% (Ϫ0.8% to 0.3%), n ϭ 4396, following SI; P ϭ 0.44].
CONCLUSIONS:
In this UK diabetes population, a move to SI Hb A 1c reporting did not lead to any marked short-term deterioration in glycemia or a different Hb A 1c outcome in patients with initial poor glucose control.
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A lack of standardization dogged the measurement of hemoglobin A 1c (Hb A 1c ) 5 for decades following its initial discovery as a glycemic marker in 1968 (1 ) . This meant that values in the same patient could vary markedly from one laboratory to another simply depending on the method of measurement used. Several global standardization initiatives were undertaken to help address this issue, including those based in Sweden and Japan (2, 3 ) . However, it was studies such as the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes and the United Kingdom Prospective Diabetes Study (UKPDS) in type 2 diabetes which truly helped cement the importance of Hb A 1c as a marker of microvascular and macrovascular complication risk and thereby further focus attention on the need for a common means of expressing results (4, 5 ) .
Because both the DCCT and the UKPDS used the same method of analysis in their studies, it was felt that one option would be for all methods to harmonize with this one. Subsequently, in the US, the National Glycohemoglobin Standardization Program (afterward renamed the NGSP) made great strides in making Hb A 1c results more comparable between different laboratories (6 ) in a currency which could be directly related to patients who participated in the DCCT and UKPDS. Similar changes were made in other countries such as the UK (7 ), and as well as having immediate benefits for patients, these developments also made international multicenter diabetes trials more feasible.
Despite these advances, there were still concerns that DCCT results did not represent the true Hb A 1c value in a patient sample, but rather the best approximation that 1980s technology could achieve. To address this situation, the IFCC announced their reference method for Hb A 1c measurement in 2002 which, given its increased specificity for Hb A 1c , reported values between 1.5% and 2% Hb A 1c , lower than the NGSP results that related to the DCCT (8 ) . As a consequence, the move over to using these numbers was resisted in some quarters because of a fear of confusion between the 2 sets of values (9 ) , with some evidence from previous changes in Hb A 1c calibration that clinicians may either undertreat or overtreat patients because they were still using older targets (10 ) . In recognition of this, the IFCC decided to change the units for Hb A 1c completely, to be expressed as millimoles per mole, which are an order of magnitude greater than if the result had been expressed as their percentage value (11 ) .
On June 1, 2009, the transition to Système International d'Unités (SI) units started in the UK with "dual reporting" of both the old DCCT and new units together (12 ) . This period ended on October 1, 2011, with the removal of the DCCT number, so results were reported solely in millimoles per mole. This current study has aimed to establish, within a mixed primary and secondary care setting, if this move to reporting just SI units subsequently led to a change in Hb A 1c values in the year following its introduction.
Patients and Methods
All patients in Hull and East Yorkshire, UK, who were identified by the laboratory computer system as being on the local diabetes register had their Hb A 1c values for the period of October 1, 2010, to September 30, 2012, collected regardless of whether they were taken in the community or in the hospital. From July 1, 2009, to September 31, 2011, the laboratory reported Hb A 1c in both percentage (NGSP/DCCT) and millimoles per mole (IFCC/SI) units. Subsequently, Hb A 1c has been reported only in SI units. It means the data collected represented a full year of results both before and after the change. Hb A 1c measurements were performed with the same 2 Menarini HA-8160 analyzers (Menarini Diagnostics Limited) and in the same central laboratory throughout the study period. Both used the same DCCT/NGSP-aligned calibrants, with SI values derived using the recognized "master equation" for conversion (13 ) . The between-assay CV of both instruments averaged 1.65% at 5.4% Hb A 1c and 1.3% at 9.3% Hb A 1c during the study period. No notifications of poor performance on external quality assessment were received for either analyzer. What instrument was used to analyze a particular Hb A 1c sample was purely a matter of chance. Patients reported as having hemoglobin variants during Hb A 1c analysis were excluded from the analysis.
Any overall difference in Hb A 1c values for the whole population for the year after the unit change was compared with that from the year before. To understand more clearly whether healthcare staff were responding any differently to an SI result compared to one that included a DCCT value, the change in Hb A 1c following an unequivocally raised result (Hb A 1c Ͼ8%) was compared before and after the units were redefined. The time between the raised result and the next Hb A 1c measurement was also compared between years.
The Mann-Whitney U-test was used to compare all before and after measurements with STATA (Statcorp LP). An arbitrary level of 5% statistical significance (2-tailed) was assumed. Fig. 1 shows the monthly mean Hb A 1c values over the 2 years. There was no difference in the overall glycemic control of the population before and after the change of unit reporting (Table 1) . Among those patients with an initial Hb A 1c value above 8% who had 2 or more measurements in the year before the unit switch, the subsequent change in their Hb A 1c result was no different from the change in Hb A 1c following a result which was reported in only SI units (Table 1) .
Results

There
Discussion
This study has shown that changing Hb A 1c units to being reported solely in the SI (mmol/mol) format has made little change to the glycemic control of a large population of patients with diabetes. The population distribution of Hb A 1c did not change in the year following implementation of the use of SI units alone, and the improvement in Hb A 1c among poorly controlled patients with initial Hb A 1c values of Ͼ8% (64 mmol/ mol) was the same whether or not a DCCT/NGSP number was included alongside an SI/IFCC result. These poorly controlled patients also had a repeat Hb A 1c measured after a similar period of time, irrespective of the units being just SI or not. Taken together, it means the way healthcare workers (and perhaps patients) act on an Hb A 1c result does not appear to have changed markedly as a consequence of changing reporting units.
Given the concern generally expressed about the effect that changing Hb A 1c units could have on clinical care, it is perhaps surprising that there was not a larger detrimental effect on glycemia than has been demonstrated here. There are several possible reasons for this. One is that the wide distribution of information on the new units to healthcare and laboratory professionals in the UK (12 ), as well as to patients themselves, before and during the period of dual result reporting may have been successful in making them more accustomed to SI. Another possible reason is that the ability of healthcare staff (comprising predominantly physicians, diabetes specialist nurses, and primary care nurses) to adapt to the new numbers was underestimated, or that they are exercising greater care with the unfamiliar units. Certainly, serious patient safety issues were not reported during the simultaneous major change in several common tests to SI units in the 1970s (14, 15 ) . Related to this, the decision by the IFCC to change the numeric index for Hb A 1c completely may indeed have helped in avoiding confusion following the unit change. Lastly, at least some healthcare staff may have demonstrated their ingenuity in being able to readily convert the new units back to the old ones.
There were limitations to this study. First, the data collected from the laboratory computers did not in- Month-year Fig. 1 ) means that the only feasible times to assess any future change in glycemia will be following each anniversary of implementation. Third, it is not possible from this analysis to establish with certainty if any confusion with units may have occurred when dual reporting was started rather than, as here, when the DCCT/NGSP value was removed. In this study's favor, all the samples from Hull and East Yorkshire were analyzed in the same laboratory and the data set is sufficiently large to detect subtle changes in population glycemia. Also, knowing that patients were recorded on the database as already having confirmed diabetes excluded the influence that using Hb A 1c for diabetes diagnosis may otherwise have had on the findings.
Most of Europe and Australasia have moved, or are currently in the process of transferring, to SI Hb A 1c units, whereas countries such as the US and Canada have stated their intention to continue with DCCT/ NGSP values, for now at least (17, 18 ) . This study gives reassurance to those nations having already changed to SI, or planning to do so, that with proper education the move can be made with little detriment to patient care.
